|
14 Nov 2019 |
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
|
|
12 Nov 2019 |
NEC and VAXIMM Announce Collaboration to Advance Personalized Neoantigen Cancer Vaccines
|
|
12 Nov 2019 |
Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
|
|
11 Nov 2019 |
OSE Immunotherapeutics Presented Positive Correlation Between Neoepitope Response and Increased Survival for NSCLC Patients Treated with Tedopi®
|
|
09 Nov 2019 |
Neon Therapeutics Announces Updated Data Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
08 Nov 2019 |
Boston Biomedical, Inc. Highlights Phase 1 Data Evaluating Investigational WT1 Cancer Peptide Vaccine DSP-7888 (ombipepimut-S*) in Patients with Advanced Malignancies at SITC 2019
|
|
08 Nov 2019 |
Immutep presents positive interim data from phase II TACTI-002 trial at SITC
|
|
08 Nov 2019 |
Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen
|
|
07 Nov 2019 |
Takeda’s Dengue Vaccine Candidate Demonstrates Protection in Children Ages Four to 16 Years, Regardless of Previous Dengue Exposure
|
|
06 Nov 2019 |
Heat Biologics Reports Positive Phase 2 Interim Data in NSCLC Patients Who Previously Failed Checkpoint Inhibitor Treatment
|
|
06 Nov 2019 |
Inovio demonstrates 80% 6-month progression-free survival in Phase 2 glioblastoma multiforme (GBM) study
|
|
06 Nov 2019 |
Gritstone Oncology Announces Data on Novel Shared Tumor-Specific Neoantigens Identified by its EDGE Platform and Contained Within its SLATE Immunotherapy
|
|
06 Nov 2019 |
Genocea Presents Preclinical Research that Shows Inhibitory Neoantigens Stifle Protective Anti-Tumor Immune Responses at Society for Immunotherapy of Cancer (SITC)
|
|
05 Nov 2019 |
FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older
|
|
30 Oct 2019 |
Unique Alzheimer's Disease Tau Vaccine Shows Great Potential in Pre-Clinical Studies
|
|
29 Oct 2019 |
Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine
|
|
29 Oct 2019 |
GSK candidate vaccine demonstrates sustained level of protection against active pulmonary tuberculosis
|
|
29 Oct 2019 |
RhoVac Receives Approval in Finland to Start Clinical Phase IIb Study in Prostate Cancer
|
|
23 Oct 2019 |
BlueWillow Receives FDA Clearance to Begin Phase 1 Study of its Intranasal Anthrax Vaccine
|
|
18 Oct 2019 |
Bavarian Nordic Updates on Phase 2 Study of CV301 in Bladder Cancer
|
|
18 Oct 2019 |
Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease
|
|
17 Oct 2019 |
Stallergenes Greer and Anergis Initiate New Study to Predict Efficacy of Second-Generation Allergen Immunotherapy
|
|
15 Oct 2019 |
Novavax Initiates Pivotal Phase 3 Clinical Trial of NanoFlu Influenza Vaccine in Older Adults
|
|
08 Oct 2019 |
Bavarian Nordic Announces Initiation of Phase 1 Clinical Trial of Equine Encephalitis Virus Vaccine
|
|
08 Oct 2019 |
Prokarium Secures £4.6M from Wellcome to Fund the Clinical Development of its Lead Vaccine Programme
|
